BVS logo

BIOVENTUS INC - A

BVSNASDAQ
πŸ† #2261 by market capEarnings Nov 2 Β· PostUS Equity
$14.87β–² $0.22 (+1.50%)
πŸŒ™ After hours$14.87β–² 0.00%Regular close Β· extended-hours price shown
πŸ””
Track BVS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.5%
7dβ–Ό 1.3%
14dβ–² 7.6%
30dβ–² 5.9%
ytdβ–² 100.1%
1yβ–² 120.3%
🏦Market Cap
$1.25B
Small Cap
πŸ“ˆRevenue Growth (YoY)
3.1%
Slowing
πŸ“ŠGross Margin
68.7%
High
πŸ’΅FCF Margin
16.2%
Healthy
βš–οΈP/S Ratio
2.1x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$14.73 – $15.09
52-Week Range
$6.47 – $15.89
Volume (shares)
444,907
Avg Volume (shares)
β€”
Shares Outstanding
84.1M
Next Earnings
2026-11-02

Fundamentals Snapshot

Annual Revenue
$568M
Last Q Revenue
$153M
P/E Ratio
22.3
P/S Ratio
2.1x
EPS (TTM)
$0.78
Dividend Yield
β€”
Dilution (1yr)
+5.3%
BVS logo

BIOVENTUS INC - A

BVS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$568Mβ–Ό βˆ’0.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
67.3%β–Ό βˆ’0.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$59Mβ–Ό βˆ’588.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$71Mβ–² +89.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
68.9Mβ–² +5.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$260Mβ–² +$34M YoY
StockOtter Β· stockotter.space

About BIOVENTUS INC - A

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Ratings

β“˜
Consensus
Buy
9 analysts
Strong Buy2
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

GlobeNewsWireΒ·2d ago

Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026

DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (β€œBioventus” or the β€œCompany”), a global leader in innovations for active healing, today announced that it will report financial results for th

GuruFocusΒ·17d ago

Bioventus Inc (BVS) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 63/100

On October 12, 2026, Bioventus Inc (BVS) shares rose 3.6% today, currently priced at $13.53. This move comes amid a 52-week range of $6.46 to $15.89.GF Value҄’

Defense WorldΒ·17d ago

Comparing Kestra Medical Technologies (NASDAQ:KMTS) & Bioventus (NASDAQ:BVS)

Bioventus (NASDAQ: BVS - Get Free Report) and Kestra Medical Technologies (NASDAQ: KMTS - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies base

Defense WorldΒ·23d ago

Reviewing Bioventus (NASDAQ:BVS) & RxSight (NASDAQ:RXST)

RxSight (NASDAQ: RXST - Get Free Report) and Bioventus (NASDAQ: BVS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength

Seeking AlphaΒ·Sep 21

Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale

Bioventus leverages cash from established products to reduce debt and fund commercial expansion, supporting a bullish outlook. BVS benefits from improved financing flexibility, with a term loan maturity extended to 2030

Zacks Investment ResearchΒ·Aug 24

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.